此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Phase II Study of Simvastatin for Relapsed/Refractory Myeloma

2017年12月27日 更新者:University of Louisville

Phase II Study of Simvastatin, Zoledronic Acid, Bortezomib, Bendamustine and Methylprednisolone for Relapsed/Refractory Myeloma

The purpose of this study test the hypothesis that the combination of simvastatin and zoledronic acid (for reversal of drug resistance), with bortezomib, high-dose methylprednisolone and bendamustine on a day 1,8 schedule (to reduce toxicity) will be an effective and well-tolerated treatment for relapsed and refractory multiple myeloma

研究概览

详细说明

OBJECTIVES

Primary To estimate the overall response rate (ORR) (complete response (CR) + very good partial response (VGPR) + partial response (PR)) of patients with multiple myeloma who have relapsed or are refractory after bortezomib treatment and will now receive a combination therapy of simvastatin, zoledronic acid, bortezomib, bendamustine and methylprednisolone.

To evaluate safety and tolerability of studied therapy.

Secondary

  1. To estimate the progression-free Survival (PFS), time to progression (TTP), overall survival (OS) and duration of response (DOR).
  2. To describe toxicities (frequency and severity) during the treatment. 3 To estimate clinical benefit response (CBR) (ORR + minor response (MR)) and stable disease (SD).

4 Explore factors associated with ORR, PFS, OS, toxicity.

研究类型

介入性

阶段

  • 阶段2

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Patients must have a diagnosis of Multiple Myeloma (using the International Myeloma Working Group Guidelines)
  • Patients must have failed at least one prior treatment regimen containing bortezomib.

They may be refractory to primary therapy or relapsed and have measurable or assessable disease. (Refractory disease is defined as anything less than PR or progression within 60 days of completing therapy.)

  • Patients with Multiple Myeloma must have measurable active, progressive or symptomatic disease. Measurable disease may be paraprotein or free light chains in serum or urine, or the presence of bone marrow plasma cells.
  • Age- must be at least 18 years of age.
  • Prior therapies may include bendamustine, bortezomib, methylprednisolone, radiation, and autologous hematopoietic cell transplant.
  • Patients who have received therapy must be at least 4 weeks beyond prior chemotherapy (excluding corticosteroids).
  • If female patient with reproductive capacity: on effective means of birth control during the entire duration of the treatment.
  • Patients must have recovered from acute toxicities resulting from therapy administered prior to entering this study to grade 1 or less. Alopecia may not be resolved.
  • Ability to understand and willingness to sign a written informed consent document.
  • Life expectancy of greater than 8 weeks.
  • ECOG performance status 0, 1, or 2 (Karnofsky > 60%; see Appendix A).
  • Patients must have adequate bone marrow function as defined below:

absolute neutrophil count > 500/ul platelets > 30,000/ul

-Patients must have adequate liver function as defined below: total bilirubin < 2 times the upper limit of normal AST(SGOT), ALT(SGPT) < 3 x upper limit of normal

  • Patients must have adequate renal function as defined by a creatinine clearance > 40 mL/min (measured or estimated by the Cockcroft-Gault formula).
  • Patients must have no signs of significant rhabdomyolysis determined by CPK levels with a CK < 5 times the upper limit of normal.

Exclusion Criteria:

  • Patients who have not received any chemotherapy treatment for multiple myeloma prior to being enrolled in the study.
  • Patients who were receiving simvastatin (dose > 40 mg/day), or the equivalent dose of another statin) during last prior chemotherapy for multiple myeloma.
  • Patients who have had chemotherapy or radiotherapy within 4 weeks prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier.
  • Patients receiving any other investigational agent(s).
  • Active second malignancy in the last 5 years except for non-melanoma skin cancer or carcinoma-in-situ.
  • History of hypersensitivity reactions attributed to simvastatin, bortezomib, bendamustine or zoledronic acid.
  • Pregnant women are ineligible, as treatment involves unforeseeable risks to the embryo or fetus.
  • Patients receiving medications that may increase risk of rhabdomyolysis such as itraconazole, ketoconazole, erythromycin, cyclosporine, amiodarone, verapamil, niacin, HIV protease inhibitors.
  • Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, myopathy, untreated hypothyroidism, hereditary myopathy in the family history, unstable angina pectoris, liver disease not due to multiple myeloma, cardiac arrhythmia that is symptomatic or not rate controlled, active connective tissue disease, active autoimmune disease, or psychiatric illness/social situations that would limit compliance with study requirements.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:不适用
  • 介入模型:单组作业
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:Treatment with combination therapy
Treatment with combination therapy of Simvastatin, Zoledronic Acid, Bortezomib, Bendamustine, and Methylprednisolone.
  1. Simvastatin 80 mg PO daily starting day -2 through day 10.
  2. Zoledronic acid 4 mg IV over 15 minutes on day 1 and then monthly
  3. Bortezomib 1.3 mg/m2/day IV bolus on days 3,6 and 10.
  4. Bendamustine 100 mg/m2/day IV over 30 minute infusion on days 3 and 10.
  5. Methylprednisolone 1g/m2 IV over 30 minutes on days 1 and 8.
其他名称:
  • Simvastatin (ZOCOR)
  • 甲基强的松龙(Medrol)
  • Bortezomib (Voltarol, Diclofenac)
  • Bendamustine (Treanda)
  • Zoledronic acid (Zometa, Reclast, Zomera)

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Response to treatment as defined by The International Myeloma Working Group response criteria for multiple myeloma.
大体时间:4 weeks after first dose of simvastatin

Response catergories (IMWG):

Complete Remission(CR), Very Good Partial Remission(VGPR), Partial Remission (PR), Minor Response (MR), Progressive Disease (PD), Stable Disease, Relapse,Refractory Disease, Overall Response.

4 weeks after first dose of simvastatin

次要结果测量

结果测量
措施说明
大体时间
Progression Free Survival (PFS)
大体时间:After 1 year of follow-up.
PFS is measured from date of study enrollment until the date of progressive disease is documented.
After 1 year of follow-up.
Incidence Rate of Toxicity
大体时间:End of study; monitoring during study.
Decriptive statistics will be provided regarding incidence rates of toxcity. Patients will be monitored for safety throughout the study.
End of study; monitoring during study.
Overall Survival (OS)
大体时间:After 1 year of follow-up
OS is measured from date of study enrollment until death.
After 1 year of follow-up

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Geoffrey Herzig, MD、James Graham Brown Cancer Center- University of Louisville

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始

2011年4月1日

初级完成 (预期的)

2018年2月1日

研究完成 (预期的)

2019年2月1日

研究注册日期

首次提交

2011年4月7日

首先提交符合 QC 标准的

2011年4月8日

首次发布 (估计)

2011年4月11日

研究记录更新

最后更新发布 (实际的)

2017年12月29日

上次提交的符合 QC 标准的更新

2017年12月27日

最后验证

2017年12月1日

更多信息

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅